Drug intelligence / Profile preview

AVS1004

Development stage: Unknown
Lead developer: Avelos Therapeutics
Modality: Small Molecules

Overview

AVS1004 is a small molecule drug in the discovery phase, developed by Avelos Therapeutics. It acts as a DNA damage modulator, targeting pathways involved in DNA damage response. The primary therapeutic area for AVS1004 is neoplasms (cancers), with its mechanism of action focused on modulating DNA damage to potentially inhibit tumor growth or enhance cancer cell death. As of the latest update, it remains in preclinical or early research stages and has not yet entered clinical trials[1].

Beyond the preview

Go deeper on AVS1004.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on AVS1004.

Explore the full profile